Visa’s Blockchain Based Innovations Can Take Small Businesses to the Next Level
9.5.2023 07:00:00 EEST | Business Wire | Press release
Visa (NYSE: V), a world leader in digital payments, was one of nine finalists tasked with exploring innovative blockchain-based use cases for the Real Digital (Brazil’s central bank-issued digital currency, or CBDC) as part of the most recent LIFT Challenge. The company partnered with Agrotoken, Microsoft, and Sinqia to develop its submission.
After months of collaborative work between each company’s world-class researchers and engineers, Visa and its team are excited to share the results of their LIFT Challenge participation — a programmable finance platform for Small and Medium Enterprises (SMEs), particularly farmers, that is designed to enable greater access to global capital markets, facilitate interoperability between currencies, improve operational processes, and uncover new growth opportunities.
Small Businesses Drive Global Economies
SMEs are often beholden to localized market structure in negotiating favorable contracts. For example, factoring is a well-known financing method today where a farmer can sell their future receivable at a discount to receive money today to purchase supplies and pay wages. This process routinely leads to a sizable percentage loss of the farmer’s receivable to the entity providing financing.
Visa’s prototype is designed to provide local farmers with more timely and greater access to a global pool of investors for financing, allowing the SMEs to get the best price discovery for their goods. By empowering SMEs with additional options to finance their businesses in a secure and frictionless way, Visa’s prototype platform aims to improve existing money movement operations and alleviate pain points caused by inaccessibility to traditional services.
“Small businesses are essential contributors to our local economies, such as in Brazil where they employ over half the population and contribute to nearly a third of the country’s GDP. At Visa, we are committed to help them grow, exploring new technologies that will empower them to more easily maintain and expand their business operations,” said Catherine Gu, Global Head of CBDC for Visa.
“Brazil is one of the world’s leading markets for innovation,” she continues. “By contributing our expertise, scale, network, and cutting-edge technologies in this market, we are able to help advance real-world applications of digital currencies — in this case making it possible for a soybean farmer to create and globally auction a tokenized contract on a permissioned version of the Ethereum blockchain, while utilizing different forms of money and interoperating between them.”
How Visa can Enable Programmable Finance in CBDCs
With many of the world’s central banks exploring the value of a Central Bank Digital Currency (CBDC), Visa and its partners have demonstrated how CBDCs can enable new cross-border payments programmatically, as well as provide international investment resources to SMEs. The programmable aspects of digital currencies, which allow delivery and payment of assets and currencies to be automatically settled only when certain conditions are met, open the door for more efficient capital usage and reduced counterparty risks, while leveraging the security, stability, and safety of a central bank liability via CBDC as a reliable settlement currency.
The prototype platform brings existing financial processes and assets on-chain, allowing farmers to tokenize traditional financing contracts. To achieve this, Agrotoken brought its agriculture-based tokenization expertise from their existing solutions in Brazil and Latin America and Visa delivered a tokenization process for turning existing Brazilian legal documents into an on-chain tradeable NFT.
“Agrotoken has a mission to democratize agribusiness by making transactions with soy and corn more accessible. To achieve this, we have chosen solid partners, such as Visa, to join us in our journey towards this goal," said Anderson Nacaxe, Director of Agrotoken in Brazil.
Combined with tokenization, Visa implemented a new onchain sealed-bid auction mechanism through smart contracts to enable a global pool of investors on the blockchain to participate in the financing process, achieving competitive price discovery. Additionally, the platform leverages a Visa technology called Universal Payments Channel (UPC) , which can interconnect between the Real Digital (CBDC) and other CBDCs, stablecoins or tokenized deposits, to help ensure future interoperability between digital currencies across different markets and networks.
This year’s LIFT Challenge Real Digital sought innovative tech research projects within the financial sector to assess use cases for the Digital Brazilian Real. Visa developed this Proof of Concept as part of the company’s ongoing efforts to work with industry partners, lead exploratory work and apply emerging technologies to creatively solve for well-known real world problems.
Visa works with Central Banks around the world and other players of the payment ecosystem to identify compelling CBDC opportunities that can be scaled and executed through secure, innovative, convenient, and reliable technologies, with the goal of developing innovative digital payment solutions that can help individuals, businesses and governments participate in the digital economy and ultimately thrive.
To learn more about Visa’s work with CBDC, visit our Digital Currency Innovation Hub. In addition, we have co-published an in-depth final report on the LIFT platform with the Brazilian Central Bank available here.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating payments transactions between consumers, merchants, financial institutions, and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable, and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at http://visa.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005774/en/
Contact information
Allee McDermott
amcdermo@visa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
